Aurobindo Pharma Buys Khandelwal Labs' Non-Oncology Business for ₹325 Cr

HEALTHCAREBIOTECH

Overview

Aurobindo Pharma Limited's subsidiary, Auro Pharma, has acquired Khandelwal Laboratories' non-oncology prescription formulation business for ₹325 crore. The deal, structured as a slump sale, aims to bolster Auro Pharma's generic pharmaceutical portfolio and market presence. Vritti Law Partners advised Khandelwal Laboratories, while Trilegal represented Auro Pharma.

Auro Pharma Acquires Khandelwal Labs' Formulation Business for ₹325 Crore

Auro Pharma Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, has finalized the acquisition of Khandelwal Laboratories Private Limited's non-oncology prescription formulation business. The transaction, valued at ₹325 crore, was conducted as a slump sale on a going-concern basis. This strategic move aims to expand Auro Pharma's footprint in key therapeutic areas outside of oncology.

Deal Mechanics and Advisors

Khandelwal Laboratories, a privately held pharmaceutical firm active in oncology, antibiotics, and pain management, divested its non-oncology segment. The sale included formulations undertaken on a going-concern basis. Vritti Law Partners provided legal counsel to Khandelwal Laboratories, managing transaction structuring, drafting, and negotiation. Trilegal advised Auro Pharma, handling due diligence, document drafting, negotiation, and closing support.

Strategic Rationale

Auro Pharma, a manufacturer and marketer of generic pharmaceuticals and APIs, seeks to integrate and grow this acquired business. The non-oncology portfolio complements Aurobindo Pharma's broader strategy to strengthen its generic drug offerings and market penetration across various therapeutic segments. This acquisition is expected to enhance Auro Pharma's product pipeline and revenue streams within India and potentially in international markets where it operates.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.